Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect




Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect

BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, president and chief executive officer, Jai Patel, chief medical officer, and Komal Joshi, chief financial officer will participate in SVB Leerink’s Biopharma Private Company Connect, taking place virtually on March 29-31, 2022.

About Imbria Pharmaceuticals

Imbria is a privately held, clinical stage, cardio-metabolic company focused on improving energy production in the mitochondria and balancing the energy supply and demand of the heart through the development of novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our lead product, ninerafaxstat (formerly IMB-101), is a novel partial fatty acid oxidation inhibitor (pFOXi) in development for a range of cardiac diseases characterized by a mismatch between energy supply and demand. Imbria is currently investigating ninerafaxstat in three Phase 2 proof of concept, indication enabling trials. IMPROVE-DiCE is a target engagement Phase 2 study in patients with diabetes at high risk of heart failure and patients with heart failure with preserved ejection fraction. Imbria also has two randomized, controlled Phase 2 clinical trials currently enrolling patients. IMPROVE-HCM in the orphan indication, non-obstructive hypertrophic cardiomyopathy and IMPROVE-ISCHEMIA in stable angina. The pipeline also includes IMB-203, designed to address energy deficiency in patients with rare inborn errors of mitochondrial metabolism. For additional information, please visit www.imbria.com.

Contacts

Komal Joshi

Imbria Pharmaceuticals, Inc.

kjoshi@imbria.com